PARP1 and ovarian cancer: The first PARP inhibitor approved as a monotherapy for the treatment of advanced ovarian cancer, olaparib, is now available for the treatment of BRCA-mutated ovarian, fallopian tube, breast, peritoneal, prostate, and metastatic pancreatic cancers.